BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8106282)

  • 1. Natural killer and lymphokine-activated killer activity in HLA-B8,DR3-positive subjects.
    Caruso C; Candore G; Colucci AT; Cigna D; Modica MA; Tantillo G; Salerno A
    Hum Immunol; 1993 Nov; 38(3):226-30. PubMed ID: 8106282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell activation in HLA-B8, DR3-positive individuals. Early antigen expression defect in vitro.
    Candore G; Cigna D; Todaro M; De Maria R; Stassi G; Giordano C; Caruso C
    Hum Immunol; 1995 Apr; 42(4):289-94. PubMed ID: 7558912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro impairment of interleukin-5 production in HLA-B8, DR3-positive individuals implications for immunoglobulin A synthesis dysfunction.
    Lio D; D'Anna C; Gervasi F; Cigna D; Modica MA; Candore G; Caruso C
    Hum Immunol; 1995 Nov; 44(3):170-4. PubMed ID: 8666553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-B8,DR3 haplotype affects lymphocyte blood levels.
    Caruso C; Bongiardina C; Candore G; Cigna D; Romano GC; Colucci AT; Di Lorenzo G; Gervasi F; Manno M; Potestio M; Tantillo G
    Immunol Invest; 1997 Apr; 26(3):333-40. PubMed ID: 9129986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro cytokine production by HLA-B8,DR3 positive subjects.
    Candore G; Cigna D; Gervasi F; Colucci AT; Modica MA; Caruso C
    Autoimmunity; 1994; 18(2):121-32. PubMed ID: 7742473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-B8,DR3 T cell impairment is completely restored by in vitro treatment with interleukin-2.
    Candore G; Colucci AT; Modica MA; Caruso C
    Immunopharmacol Immunotoxicol; 1991; 13(4):551-61. PubMed ID: 1774436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individual susceptibility to hexavalent chromium of workers of shoe, hide, and leather industries. Immunological pattern of HLA-B8, DR3-positive subjects.
    Mignini F; Streccioni V; Baldo M; Vitali M; Indraccolo U; Bernacchia G; Cocchioni M
    Prev Med; 2004 Oct; 39(4):767-75. PubMed ID: 15351544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective expression of CD95 (FAS/APO-1) molecule suggests apoptosis impairment of T and B cells in HLA-B8, DR3-positive individuals.
    Stassi G; Todaro M; De Maria R; Candore G; Cigna D; Caruso C; Galluzzo A; Giordano C
    Hum Immunol; 1997 Jun; 55(1):39-45. PubMed ID: 9328788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble interleukin-2 receptor secretion defect in vitro in HLA-B8, DR3 positive subjects.
    Modica MA; di Lorenzo G; Galluzzo A; Giordano C; Portelli MR; Candore G; Caruso C
    Autoimmunity; 1990; 7(2-3):87-96. PubMed ID: 2104185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-B8,DR3 phenotype and lymphocyte responses to phytohaemagglutinin.
    Modica MA; Cammarata G; Caruso C
    J Immunogenet; 1990; 17(1-2):101-7. PubMed ID: 2212697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA A1, B8, DR3 extended haplotypes in autoimmune chronic hepatitis.
    Tait B; Mackay IR; Board P; Coggan M; Emery P; Eckardt G
    Gastroenterology; 1989 Aug; 97(2):479-81. PubMed ID: 2787258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of cytokine patterns in subjects bearing the HLA-B8,DR3 phenotype: implications for autoimmunity.
    Lio D; Candore G; Romano GC; D'Anna C; Gervasi F; Di Lorenzo G; Modica MA; Potestio M; Caruso C
    Cytokines Cell Mol Ther; 1997 Dec; 3(4):217-24. PubMed ID: 9740350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of a lymphocyte abnormality associated with HLA-B8/DR3 in clinically healthy individuals.
    Hashimoto S; McCombs CC; Michalski JP
    Clin Exp Immunol; 1989 Jun; 76(3):317-23. PubMed ID: 2787712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance/susceptibility to Echinococcus multilocularis infection and cytokine profile in humans. II. Influence of the HLA B8, DR3, DQ2 haplotype.
    Godot V; Harraga S; Beurton I; Tiberghien P; Sarciron E; Gottstein B; Vuitton DA
    Clin Exp Immunol; 2000 Sep; 121(3):491-8. PubMed ID: 10971516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated natural killer cytotoxicity in HLA-B8 and HLA-DR3-positive individuals.
    Jakobisiak M; Saidman S; Schlaut J; Pazderka F; Dossetor JB
    Immunol Lett; 1986 Mar; 12(2-3):61-3. PubMed ID: 3087867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common HLA-B8-DR3 haplotype in Northern India is different from that found in Europe.
    Witt CS; Price P; Kaur G; Cheong K; Kanga U; Sayer D; Christiansen F; Mehra NK
    Tissue Antigens; 2002 Dec; 60(6):474-80. PubMed ID: 12542740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
    Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-alpha(-308) G/A polymorphism.
    Mäkelä S; Mustonen J; Ala-Houhala I; Hurme M; Partanen J; Vapalahti O; Vaheri A; Pasternack A
    J Infect Dis; 2002 Sep; 186(6):843-6. PubMed ID: 12198621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin genes, HLA-B8/DR3, and immune responsiveness to primary immunogen and mitogens in normal subjects.
    Kallenberg CG; Klaassen RJ; Westra J; Beelen JM; Ockhuizen T
    Clin Immunol Immunopathol; 1988 Jun; 47(3):333-42. PubMed ID: 3259481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Extended" A1, B8, DR3 haplotype shows remarkable linkage disequilibrium but is similar to nonextended haplotypes in terms of diabetes risk.
    Ide A; Babu SR; Robles DT; Wang T; Erlich HA; Bugawan TL; Rewers M; Fain PR; Eisenbarth GS
    Diabetes; 2005 Jun; 54(6):1879-83. PubMed ID: 15919812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.